Evidence map›Paper›PMID 39254779›Full record

ReviewCellular oncology (Dordrecht, Netherlands)2025

BHLHE41, a transcriptional repressor involved in physiological processes and tumor development.

Caroline Bret, Fabienne Desmots-Loyer, Jérôme Moreaux, Thierry Fest

Abstract readReview
In one paragraph

Review in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Caroline BretDepartment of Biological Hematology, CHU Montpellier, Montpellier, 34295, France. caroline.bret@umontpellier.fr.ORCID http://orcid.org/0000-0003-4784-2566
Fabienne Desmots-LoyerUMR 1236, University of Rennes 1, INSERM, Établissement Français du Sang Bretagne, Rennes, France. fabienne.desmots-loyer@univ-rennes.fr.ORCID http://orcid.org/0009-0009-9161-6903
Jérôme MoreauxDepartment of Biological Hematology, CHU Montpellier, Montpellier, 34295, France. jerome.moreaux@igh.cnrs.fr.ORCID http://orcid.org/0000-0002-5717-3207
Thierry FestUMR 1236, University of Rennes 1, INSERM, Établissement Français du Sang Bretagne, Rennes, France. thierry.fest@univ-rennes.fr.ORCID http://orcid.org/0000-0002-6437-4189

Funding

Agence Nationale de la Recherche ANR-18-CE15-0010-01 PLASMADIFF-3DAssociation pour la Recherche contre le Cancer ARC, RAC21060NNAAssociation pour la Recherche contre le Cancer PGA EpiMM3DHORIZON EUROPE Reforming and enhancing the European Research and Innovation system HORIZON-MISS-2021-CANCER-02Institut National Du Cancer INCA PLBIO18-362PIT-MMMSD Avenir EpiMUM3D
6 · The paper itself

Abstract

BHLHE41 is a nuclear transcriptional repressor that belongs to the basic helix-loop-helix protein superfamily. BHLHE41 expression tends to be restricted to specific tissues and is regulated by environmental cues and biological events. BHLHE41 homodimerizes or heterodimerizes with various partners, influencing its transcription factor function. BHLHE41 is involved in the regulation of many physiological processes implicated in tissue/organ homeostasis, such as myogenesis, adipogenesis, circadian rhythms and DNA repair. At cellular level, BHLHE41 is involved in the regulation of mesenchymal stem cell properties, tissue-specific macrophage functions and lymphoid lineage physiology. In several cancer types, BHLHE41 modulates the expression of different transcriptional programs influencing cell cycle control, apoptosis, invasiveness, epithelial to mesenchymal transition and hypoxia response in the tumor environment. Depending on the cancer cell type, BHLHE41 can act as a tumor suppressor or an oncogene, and could be a target for innovative therapies. This review summarizes the available knowledge on BHLHE41 structure, biological functions, regulation and potential partners, as well as its role in physiological processes, and its implication in major cancer steps.

Indexed as

Basic Helix-Loop-Helix ProteinsCarcinogenesisNeoplasmsRepressor ProteinsAnimalsGene Expression Regulation, NeoplasticHumansBasic Helix-Loop-Helix ProteinsBHLHE41 protein, humanRepressor ProteinsBHLHE41CancerHomeostasisNuclear transcriptional repressor

Identifiers

PMID39254779
PMCPMC11850569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.